2013
DOI: 10.1182/blood.v122.21.1586.1586
|View full text |Cite
|
Sign up to set email alerts
|

Modified Dose Escalation Of Ruxolitinib: A Feasible Therapeutic Approach In The Management Of Myelofibrosis

Abstract: Ruxolitinib, is a JAK1/2 inhibitor approved for the treatment of intermediate and high risk myelofibrosis (MF). The recommended starting doses for ruxolitinib, are 20 mg PO BID or 15 mg PO BID if platelet (PLT) counts are ≥200 x109/L or 100 to 200 x109/L, respectively. However, drug related side effects which includes grade 3/4 anemia (45.2%), thrombocytopenia (12.9%), fatigue (25.2%) and diarrhea (23.2%) are common using standard dosing. Moreover 70% of patients (pts) started on the standard regimen require d… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2014
2014
2017
2017

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…There is increasing literature suggesting that lower starting doses of ruxolitinib should be used, with uptitrations depending on safety and efficacy in anemic patients [44][45][46][47]. In our opinion, temporary decreases in Hb levels should be treated with transfusion in young patients with Hb levels <7.5 g/dL and older patients with Hb levels <8 g/dL.…”
Section: Anemiamentioning
confidence: 99%
“…There is increasing literature suggesting that lower starting doses of ruxolitinib should be used, with uptitrations depending on safety and efficacy in anemic patients [44][45][46][47]. In our opinion, temporary decreases in Hb levels should be treated with transfusion in young patients with Hb levels <7.5 g/dL and older patients with Hb levels <8 g/dL.…”
Section: Anemiamentioning
confidence: 99%
“…In patients requiring modifications from the starting dose, clinical evidence suggests that ruxolitinib can be effective long-term at titrated doses as low as 10 mg twice daily [ 82 84 ]. In trials of patients with MF with low platelet counts (between 50 and 100 × 10 9 /L), dosing of ruxolitinib was initiated at 5 mg twice daily followed by escalation by 5 mg daily every 4 weeks to 10 mg twice daily or higher in patients with adequate platelet counts [ 83 , 85 ].…”
Section: Ruxolitinib For Myelofibrosismentioning
confidence: 99%